Sjögren’s syndrome patients had bad news this past summer when medical professionals learned at the EULAR Annual Congress in Madrid that Bristol-Myers Squibb reported its abatacept, considered a lead investigational treatment candidate, failed during a Phase III trial. There is no drug approved by the FDA for primary Sjögren’s syndrome.
Recently Steven E. Carsons, chief of rheumatology division at NYU Winthrop Hospital, and a senior associate dean for translational medicine at NYU Long Island School of Medicine, noted in a Healio article that this is partially due to the wide spectrum of clinical involvements related to the disease.
Just a handful of years ago, there was little pipeline. That has changed, reports Judith James, MD, PhD Professor and chair of the arthritis and clinical immunology research program at the Oklahoma Medical Research Foundation.
In fact, Healio reports more than 40 ongoing clinical trials focusing on the disease including:
- Filgotinib plus lanraplenib plus triabrutinib (Galapagos/Gilead/Onco)
- Benlysta (belimumab, GSK)
- Ianalumab and iscalimab (Novartis)
- Tibulizumab (Lilly)
Steven E. Carsons, chief of rheumatology division at NYU Winthrop Hospital, and a senior associate dean for translational medicine at NYU Long Island School of Medicine
Call to Action: Do you or a loved one have a Sjögren’s syndrome diagnosis? Let us know at TrialSite News as we can offer more granular information about these clinical studies if interested. Sign up for the Daily Digest for updates.